Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2005
03/16/2005CN1593223A Active nutritious health oral liquid of donkey-hide gelatin
03/16/2005CN1193096C Operation for onzyme activity of protoporphyrin prooxidase in eukaryotic organism
03/16/2005CN1193041C New human protein with the function of inhibiting cancer cell growth and its encoding sequence
03/16/2005CN1193040C New human protein with the function of inhibiting tumor cell growth and its encoding sequence
03/16/2005CN1192799C Adjuvant combination formulations
03/16/2005CN1192796C Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
03/16/2005CN1192766C Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable De/association rates
03/15/2005US6867299 Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents
03/15/2005US6867292 Characterization of novel gene cbl-SL
03/15/2005US6867291 Human hemicentin proteins and polynucleotides encoding the same
03/15/2005US6867289 Thio-modified aptamer synthetic methods and compositions
03/15/2005US6867288 Polycystic kidney disease gene
03/15/2005US6867284 Fluorinated oligopeptides especially those having 4,4-difluoro- 2-amino butyric acid at the C terminus
03/15/2005US6867215 Cardioprotective phosphonates and malonates
03/15/2005US6867208 Vitronectin receptor antagonists, their preparation and their use
03/15/2005US6867202 Treatment of insulin resistance
03/15/2005US6867197 Method of targeting conjugate molecules to mitochondria
03/15/2005US6867193 Prevents onset of hepatic encephalopathy
03/15/2005US6867192 Inhibiting eosinophil infiltration into lungs; such as 2-((-2-((2-(2-Benzoylphenoxy)acetyl)amino)-4-methylpentanoyl)-amino)-3-(4 -(((4-((2-phenylacetyl)amino)-1-piperidinyl)-carbonyl)oxy)phenyl)propanoic acid
03/15/2005US6867191 Preparation and use of oligopeptide lyophilisate for gonad protection
03/15/2005US6867190 Methods of therapy with thrombin derived peptides
03/15/2005US6867189 Such as obesity, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension
03/15/2005US6867186 Anticancer agents
03/15/2005US6867185 Inhibitors of hepatitis C virus
03/15/2005US6867184 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
03/15/2005US6867182 Composition of a polypeptide and an amphiphilic compound in an ionic complex and the use thereof
03/15/2005US6867179 Methods of inducing hair growth and coloration
03/15/2005US6867178 Calorically dense nutritional composition
03/15/2005US6867177 CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
03/15/2005US6867043 Controlling gene expression in cells; anticancer agents; drug delivery
03/15/2005US6867039 Oligonucleotides, specifically hybridizable with nucleic acids encoding dual specific phosphatase 5
03/15/2005US6867033 By administration of PV virus-like particles (VLPs) to a patient suffering from the PV infection
03/15/2005US6867024 Ubiquinone composition and methods related thereto
03/15/2005US6867016 Reagents and methods useful for detecting diseases of the gastrointestinal tract
03/15/2005US6867007 Binary or polynary targeting and uses thereof
03/15/2005US6867006 Use in stem cell mobilization, neuronal protection, and regulating hematopoiesis; inhibiting destruction of hematopoietic progenitor cells resulting from chemotherapy
03/15/2005US6866991 Methods for promoting growth of bone, ligament, and cartilage using zvegf4
03/15/2005US6866869 Liquid antimicrobial compositions
03/15/2005US6866851 GFRα1-RET specific agonists and methods therefor
03/15/2005US6866850 Prevention and treatment of amyloidogenic disease
03/15/2005US6866849 Administering an A beta peptide to induce immune response; monitoring and detecting antibodies having A beta binding specificity; Alzheimer*s disease
03/15/2005US6866848 Diagnosis and therapy of immune disorders induced by inhibitors of blood-coagulation factor VIII and inhibitors to binding of von Willebrand factor and/or membrane phosphatides
03/15/2005US6866844 Genetically engineered; treatment of mucopolysaccharidosis VI (MPS V1) or Maroteaux-Lamy syndrome; purity measured using reverse-phase high performance liquid chromatography
03/15/2005US6866843 Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell
03/15/2005US6866837 Bombesin analogs wherein the first and optionally the third amino acid are modified bind to gastrin releasing peptide receptors
03/15/2005US6866782 Process for the purification of pharmacologically active proteins through cationic exchange chromatography
03/15/2005CA2255659C Neuroactive peptides
03/15/2005CA2191769C Dialysis fluid containing peptides obtained from casein as osmotic agents and bicarbonate ions as buffering agents
03/15/2005CA2170034C Recombinant humanized anti-human immunodeficiency virus antibody
03/15/2005CA2124964C Cdw52-specific antibody for treatment of multiple sclerosis
03/15/2005CA2068069C Blood coagulation factor xi concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
03/15/2005CA2054325C Antisense oligonucleotides for treatment of cancer
03/10/2005WO2005022160A2 Diagnosis and treatment of micobacterial infections
03/10/2005WO2005021757A1 Polypeptides and polynucleotides for use as a medicament
03/10/2005WO2005021756A1 Anti-angiogenic peptides from the n-terminus of endostatin
03/10/2005WO2005021754A1 Gp131: methods and compositions for treating cancer
03/10/2005WO2005021750A1 Treatment of menorrhagia, dysmenorrhoea or endometriosis
03/10/2005WO2005021741A2 Diagnostics and therapeutics for diseases associated with kallikrein 11 (klk11)
03/10/2005WO2005021722A2 METHODS AND COMPOSITIONS FOR INHIBITION OF NUCLEAR FACTOR κB
03/10/2005WO2005021706A2 Delivery of compounds with rehydrated blood cells
03/10/2005WO2005021593A1 Fusion polypeptides, and use thereof in antivascular tumor therapy
03/10/2005WO2005021592A2 Enhancing the circulating half-life of interleukin-2 proteins
03/10/2005WO2005021584A2 Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
03/10/2005WO2005021580A2 Hydrogels for modulating cell migration and matrix deposition
03/10/2005WO2005021579A2 Epo mimetic peptides and fusion proteins
03/10/2005WO2005021575A2 Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties
03/10/2005WO2005021557A2 Poly-pegylated protease inhibitors
03/10/2005WO2005021556A2 Modified protease inhibitors
03/10/2005WO2005021494A2 D-amino acid peptides
03/10/2005WO2005021065A2 Indirect delivery of growth factors into the central nervous system
03/10/2005WO2005021064A2 Delivery of therapeutic compounds to the brain and other tissues
03/10/2005WO2005021037A1 Composition comprising a pulmonary surfactant and a pde2 inhibitor
03/10/2005WO2005021028A1 Use of modified cyclosporins for the treatment of hcv disorders
03/10/2005WO2005021027A1 Collagen hydrolysate
03/10/2005WO2005021026A2 Methods for treating or ameliorating ghrelin-associated diseases and disorders
03/10/2005WO2005021024A1 Amino acid derived prodrugs of propofol, compositions and uses thereof
03/10/2005WO2005021023A1 Therapeutical conversion
03/10/2005WO2005021022A2 Stable formulations of peptides
03/10/2005WO2005021011A1 Use of surfactant preparations for the treatment of surgical adhesions
03/10/2005WO2005020984A2 Method of reducing the risk of oxidative stress
03/10/2005WO2005020972A2 Combination therapy for the treatment of ocular neovascular disorders
03/10/2005WO2005020970A2 Protease inhibitor compositions for prevention and treatment of skin conditions
03/10/2005WO2005020962A1 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
03/10/2005WO2005020928A2 Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
03/10/2005WO2005020918A2 Ultrasonic concentration of drug delivery capsules
03/10/2005WO2005020916A2 Myoblast treatment of diseased or weakened organs
03/10/2005WO2005020902A2 Compositions and methods for treating and diagnosing irritable bowel syndrome
03/10/2005WO2005020898A2 Methods of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i)
03/10/2005WO2005020879A2 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
03/10/2005WO2005005436A3 Cross-linked glycopeptide-cephalosporin antibiotics
03/10/2005WO2005003288A3 Diagnostic methods , prognostic methods and pharmaceutical compositions for neurodegenerative diseases like alzheimer’s disease by modulating and investigating genes rgs4 and itpkb, their gene products or fragments and derivatives thereof
03/10/2005WO2005000355A8 Treatment of tumor by cotransferring chemotherapeutic agent with cytokine gene
03/10/2005WO2004103285A3 Lactoferrin in the treatment of diabetes mellitus
03/10/2005WO2004094996A3 System and method for determining differential protein expression, diagnostic biomarker discovery system and method of using the same, and protein biomarkers and therapeutic and diagnostic uses thereof
03/10/2005WO2004094641A3 A novel method of modulating bone-realted activity
03/10/2005WO2004091497A3 Methods and compositions for increasing the anaerobic working capacity in tissues
03/10/2005WO2004090112A3 Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
03/10/2005WO2004085654A3 Modulation of cell phenotype by inhibitory rna
03/10/2005WO2004081040A3 Insulin-like growth factor (igf-i) plasmid-mediated supplementation for therapeutic applications
03/10/2005WO2004081031A3 Thiol-mediated drug attachment to targeting peptides
1 ... 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 ... 3163